| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() AUA MEETING: Muse Offers Second Chance For Patients Unsuccessful With Viagra DALLAS, TX - May 6, 1999 -- Tulane University School of Medicine today reported data at the 94th annual meeting of the American Urologic Association confirming the safety and efficacy of Vivus Inc.’s Muse(R) (alprostadil) in patients who were unsuccessful with Pfizer Inc.’s Viagra(R) (sildenafil citrate) due to lack of efficacy or side effects of treatment. "In my practice, I have found that for many men with erectile dysfunction Viagra is either contraindicated or ineffective. Muse is the ideal alternative for these patients," said Dr. Wayne Hellstrom, professor of urology, Tulane University School of Medicine, and lead author of the abstract. The study evaluated patients who had failed to respond to Viagra or who had experienced side effects resulting in discontinuation of Viagra. The study enrolled 367 patients at 73 clinical sites and 285 patients completed the end-of-study-questionnaire. At the conclusion of the eight-week study, 71 percent of patients reported improvement in their erections with Muse. Sixty-five percent of patients chose to continue using Muse as their erectile dysfunction therapy. Related Links: Muse, Vivus Inc., Viagra, Pfizer Canada Inc.
|